ANX-042 / Mayo Clinic, Anexon - LARVOL DELTA

ANX-042 Aim 1: Safety and Efficacy of ANX-042 in Human Cardiorenal Syndrome (clinicaltrials.gov) - P1 | N=40 | Completed | Sponsor: Mayo Clinic | Enrolling by invitation ➔ Completed | N=60 ➔ 40

Enrollment change • Trial completion • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypotension • Nephrology • Renal Disease

ANX-042 Aim 1: Safety and Efficacy of ANX-042 in Human Cardiorenal Syndrome (clinicaltrials.gov) - P1 | N=60 | Enrolling by invitation | Sponsor: Mayo Clinic | Trial completion date: Dec 2023 ➔ Dec 2024 | Trial primary completion date: Dec 2023 ➔ Dec 2024

Trial completion date • Trial primary completion date • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypotension • Nephrology • Renal Disease

ANX-042 Aim 1: Safety and Efficacy of ANX-042 in Human Cardiorenal Syndrome (clinicaltrials.gov) - P1 | N=60 | Enrolling by invitation | Sponsor: Mayo Clinic | Trial completion date: Sep 2023 ➔ Dec 2023 | Trial primary completion date: Jul 2023 ➔ Dec 2023

Trial completion date • Trial primary completion date • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypotension • Nephrology • Renal Disease